Clinical trials
Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 6,202 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07408531Recruiting
AI-enhanced lung cancer screening study
This trial uses artificial intelligence to better predict your lung cancer risk from your low-dose CT scan. You will watch a short video, answer a survey, and optionally give a blood sample to help improve future screening.
Chicago, IllinoisAges 50–80 - NCT06821503RecruitingPhase 1/Phase 2
Study of LM-108 with chemo for advanced pancreatic cancer
This trial tests a new drug called LM-108 combined with chemotherapy for people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if it's safe and may help shrink tumors or stop them from growing.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06804395Recruiting
Community cancer screening registry study
This study creates a registry to better understand and improve cancer screening for people at higher risk. By joining, you help researchers learn how to prevent and manage cancer in your community.
Totowa, New JerseyAges 18 years+ - NCT06825715Recruiting
Precision oncology support for lung and prostate cancer
This study tests a program to help veterans with lung or prostate cancer get personalized cancer treatments. The goal is to see if extra support for doctors and patients leads to better use of precision medicine.
New York, New YorkAges Any age - NCT06736275RecruitingEarly Phase 1
Testing a new gene therapy for advanced solid tumors
This trial tests an experimental gene therapy called SXRN for people with advanced solid tumors that haven't responded to standard treatments. The study aims to see if it's safe and may help slow the disease.
BeijingAges 18–75 - NCT06789679RecruitingPhase 2
Adding S-1 to standard chemo for advanced pancreatic cancer
This trial tests whether adding a third drug (S-1, a chemotherapy pill) to the standard two-drug IV chemo (albumin-bound paclitaxel and gemcitabine) can help people with advanced pancreatic cancer live longer. It's for those who haven't had treatment yet for their advanced cancer.
Beijing, Chaoyang DistrictAges 18 years+ - NCT06518135Recruiting
Sentinel node biopsy after chemo for initial node-positive breast cancer
This trial checks whether a less invasive sentinel lymph node biopsy (removing just a few nodes) can safely replace full lymph node removal for people whose breast cancer and underarm lymph nodes responded well to chemotherapy. It is for patients who initially had 1 to 3 involved nodes and now appear cancer-free in the armpit.
Henan, HenanAges 18–70 - NCT06527300RecruitingPhase 2
Study of NHWD-870 for advanced NUT cancer
This trial tests a new drug called NHWD-870 for people with NUT cancer (a rare cancer linked to a gene change). The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
ChongqingAges 12–75 - NCT06362980RecruitingPhase 1
BPI-1178 plus osimertinib for EGFR-mutated lung cancer
This trial tests a new drug (BPI-1178) combined with osimertinib for advanced lung cancer with EGFR mutations. It’s for people whose cancer has progressed after prior treatment with a third-generation EGFR targeted therapy.
BeijingAges 18 years+ - NCT06470971RecruitingPhase 2
Siltuximab to prevent severe side effects during immunotherapy rechallenge
This trial tests if siltuximab can prevent severe immune-related side effects when patients restart immunotherapy (anti-PD-1/PD-L1) after previous severe side effects. It aims to make rechallenge safer for people with advanced cancer.
Columbus, OhioAges 18 years+ - NCT06276686RecruitingEarly Phase 1
Exercise With Chemoradiotherapy for Locally Advanced Rectal Cancer
This study tests whether adding regular exercise during your standard chemoradiotherapy can help the treatment work better for people with locally advanced rectal cancer. It is designed for patients who have already been offered this type of therapy before surgery.
Cottingham, East YorkshireAges 18 years+ - NCT06301399RecruitingPhase 2
Rituximab with prior therapy for advanced liver cancer
This trial tests if adding rituximab to previous cancer treatments can help people with advanced hepatocellular carcinoma (a type of liver cancer) that has stopped responding or caused side effects. It aims to see if this combination is safe and effective.
Tianjin, Tianjin MunicipalityAges 17–79 - NCT06028022RecruitingPhase 2
Reishi mushroom for fatigue and joint/muscle pain in breast cancer
This trial tests whether a reishi mushroom extract can help reduce fatigue and joint or muscle pain in people with breast cancer who are taking aromatase inhibitors. If you have these symptoms, you may be able to join.
Albert Lea, MinnesotaAges 18 years+ - NCT06026605RecruitingEarly Phase 1
Study of WTX212A for advanced solid tumors
This trial tests a new drug called WTX212A for people with advanced solid tumors that are no longer responding to standard treatments. The goal is to find the best dose and see if the drug is safe and effective.
Hangzhou, ZhejiangAges 18–75 - NCT05710679Recruiting
Blood test predicts leftover cancer after intensified head and neck radiation
This study uses a blood test to see whether cancer DNA is still detectable after a stronger combination of radiation and chemotherapy for locally advanced head and neck cancer. The goal is to predict who may have “residual” (remaining) disease and help guide future care.
Clermont-Ferrand, Puy-de-DômeAges 18–80 - NCT05663775RecruitingPhase 2
Mesalamine to prevent bowel inflammation after melanoma immunotherapy
This study tests whether taking mesalamine can prevent colitis (bowel inflammation) in people with advanced melanoma who are treated with ipilimumab plus nivolumab. It may help reduce dangerous stomach or bowel side effects from this cancer treatment.
Edmonton, AlbertaAges 18 years+ - NCT05378919RecruitingPhase 2
Testing new pre-surgery treatment for locally advanced rectal cancer
This Phase 2 trial compares a pre-surgery (neoadjuvant) treatment plan versus the standard plan for people with stage II–III rectal cancer. The goal is to see which approach works better and is safe before surgery.
KaunasAges 18 years+ - NCT05392699RecruitingPhase 1
Testing ABOD2011 for advanced solid tumors after standard treatment
This Phase 1 trial tests a new medicine (ABOD2011) in people with advanced solid tumors that have come back or spread after standard treatment. It may help by shrinking tumors and allows researchers to study the tumor by giving medicine directly into it and taking a biopsy.
BeijingAges 18 years+ - NCT04906434RecruitingPhase 1
Study of ABSK-011 for advanced solid tumors
This early-phase study tests how safe ABSK-011 is, what side effects it causes, and how the body processes the drug. It may help certain patients with advanced solid cancers (including some liver cancer cases) whose tumors have specific test results.
Phoenix, ArizonaAges 18–75 - NCT04945330Recruiting
Study for NTRK fusion cancers taking larotrectinib
This trial is for people with advanced or returning solid tumors that have specific gene changes called NTRK gene fusions. It looks at patients who are already being treated with larotrectinib as part of normal care, to understand this treatment in real life.
Multiple LocationsAges Any age - NCT05057052RecruitingPhase 2
Freezing liver tumors with immunotherapy and a pill drug
This Phase 2 trial tests whether freezing (cryoablation) plus sintilimab (an immune system medicine) and regorafenib (a pill) can shrink colorectal cancer that has spread to the liver. It is for people whose cancer has come back or progressed after at least two prior chemotherapy treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05222087RecruitingPhase 1
Radiation for newly diagnosed metastatic lung cancer without driver mutations
This early study tests whether a specific kind of radiation can be safely given to people with newly diagnosed metastatic lung cancer when cure isn’t possible. It’s meant to see how well the treatment can be delivered and how it affects outcomes in a specific genetic group of tumors.
Southport, QueenslandAges 18 years+ - NCT05394831RecruitingPhase 1/Phase 2
Study of an EGFR-targeted drug for advanced lung cancer
This trial tests a new drug (JIN-A02) in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has specific EGFR mutations. It mainly checks whether the treatment is safe and tolerable, and how the body handles the drug, with possible benefit depending on your mutation type.
Orange, CaliforniaAges 18 years+ - NCT04762641RecruitingPhase 1
First-dose safety study of ABL503 for advanced cancers
This Phase 1 trial tests the safety and side effects of ABL503 and finds the best dose to study next. It is for people with advanced cancer that is growing despite prior treatment options.
Duarte, CaliforniaAges 18 years+
Hear when a new Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 6,202 recruiting advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.